Lead: Injectable-Only Overlapping Buprenorphine Starting Protocol in a Low-Threshold Setting
Échec de l'ajout au panier.
Échec de l'ajout à la liste d'envies.
Échec de la suppression de la liste d’envies.
Échec du suivi du balado
Ne plus suivre le balado a échoué
Lead: Injectable-Only Overlapping Buprenorphine Starting Protocol in a Low-Threshold Setting
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Injectable-Only Overlapping Buprenorphine Starting Protocol in a Low-Threshold Setting
JAMA Network Open
Injectable-only buprenorphine protocols are an exciting new strategy for buprenorphine initiation, particularly in the fentanyl era. This is a cohort study of 95 patients with moderate to severe opioid use disorder who received care in a low-threshold setting in Seattle. 79% of patients included in the study were experiencing homelessness or living in permanent supportive housing. Patients selected a long-acting injectable (LAI) buprenorphine initiation protocol which included three escalating doses of LAI buprenorphine over three days, with no sublingual buprenorphine and without cessation of fentanyl/opioid use. 75% of the patients completed the protocol, and 64% received a second monthly dose of LAI buprenorphine.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM